2018欧洲专家共识_临床应用富马酸二甲酯治疗中重度斑块型银屑病.pdfVIP

DOI: 10.1111/jdv.15218 JEADV CONSENSUS MEETING REPORT Clinical use of dimethyl fumarate in moderate-to-severe plaque-type psoriasis: a European expert consensus U. Mrowietz,1,* J. Barker,2 W.-H. Boehncke,3,4 L. Iversen,5 B. Kirby,6 L. Naldi,7,8 K. Reich,9 A. Tanew,10 P.C.M. van de Kerkhof11 R.B. Warren12,13 1Psoriasis-Centre at the Department of Dermatology, University Medical Centre Schleswig-Holstein, Kiel, Germany 2St John’s Institute of Dermatology, King’s College London, London, UK 3Division of Dermatology and Venereology, Geneva University Hospitals, Geneva, Switzerland 4Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland 5Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark 6Department of Dermatology, St. Vincent’s University Hospital, Dublin, Ireland 7Centro Studi GISED, Bergamo, Italy 8Department of Dermatology, Ospedale san Bortolo di Vicenza, Vicenza, Italy 9Dermatologikum Berlin and SCIderm Research Institute, Hamburg, Germany 10Department of Dermatology, Medical University of Vienna, Vienna, Austria 11Department of Dermatology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands 12Dermatology Centre, Salford Royal NHS Foundation Trust, Salford, UK 13Manchester Academic Health Science Centre, Manchester NIHR Biomedical Research Centre, The University of Manchester, Manchester, UK *Correspondence: U. Mrowietz. E-mail: umrowietz@dermatology.uni-kiel.de Abstract Fumaric acid esters (FAEs) are a group of small molecules that were first investigated for the treatment of psoriasis in 1959. The first fumarate-based drug – Fumaderm – was approved in Germany in 1994 for severe psoriasis and then in 2008, the label was expanded to include moderate psoriasis. Fumaderm is a combination of different FA